Brief: Phio Presents Positive Data At ASGCT Showing Ph-762 Enhanced Antitumor Efficacy Of CAR-T Cells
11/05/2021 13:35
May 11 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS PRESENTS POSITIVE IN VIVO DATA AT
ASGCT
SHOWING PH-762 SIGNIFICANTLY ENHANCED ANTITUMOR EFFICACY OF
HER2-TARGETED CAR-T CELLS
Source text for Eikon: ID:nPn6FhwvPa
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing